TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
ASCO 2023 Annual Meeting Poster Presentation Potential predictive biomarker for clinical response |
Press Release2023, September 22 08:00 a.m. TME Pharma announces selection of two clinical abstracts on the ongoing NOX-A12 GLORIA Phase 1/2 trial in glioblastoma for presentation at ESMO 2023 congress and SNO 2023 Annual Meeting 2023, September 13 08:00 a.m. NOX-A12 combination regimen with bevacizumab: 17-month survival rate exceeds all relevant competitor treatments against most severe form of adult brain cancer 2023, July 20 06:00 p.m. Half-yearly report on the liquidity contract with invest securities |
EventsKOL Webinar on the new biomarker with potential to select brain cancer patients most likely to respond best to NOX-A12 treatment
Dr. Frank A. Giordano, Prof. Michael Hölzel, Aram Mangasarian ESMO Congress 2023
October 20 – 24 | Madrid, Spain HTID Paris
October 24- 25 | Paris, France Bio Europe Autumn
November 6 – 8 | Munich, Germany Investival Showcase
November 13 | London, United Kingdom |